About Us
Indapta is a biotechnology company seeking to harness the natural power of the immune system to fight hematologic and solid cancers with our universal G-NK cell platform. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRγ-deficient natural killer cells, known as G-NK cells. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies.
G-NK cell therapy is an off-the-shelf solution, eliminating the need for a patient-specific therapy.
G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies.
Leadership
Ronald Martell
Chairman of the Board and Co-Founder
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Guy DiPierro
Chief Strategy Officer and Co-Founder
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Austin Bigley, PH.D.
VP of Research
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Robert Sikorski, MD
Acting Chief Medical Officer
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Product Portfolio
Cancer is the leading cause of death worldwide. Current therapies are suboptimal, frequently ineffective and often cause significant side effects.
Immunotherapies are a formidable new mechanism to fight cancer. Designed to boost the immune response, immunotherapies such as G-NK therapy were developed to address the limitations of currently available autologous T-cell therapies.
Natural killer (NK) cells are the immune system’s first responders against cancer and pathogens that cause infectious diseases. Indapta Therapeutics believes that NK cell therapy has immense potential to be used in the development of cutting-edge cancer therapies for various tumor types.
Indapta’s NK cell therapy product stems from a naturally occurring and highly potent type of NK cell, known as G-NK cells. Engineered by nature to fight cancer, G-NK cells have enhanced anti-tumor activity due to an epigenetic change resulting in the absence of the FcRγ chain. Indapta’s proprietary expansion process improves the functionality, reproducibility and persistence of these G-NK cells without the need for artificial genetic engineering.
Indapta then combines these G-NK cells with FDA-approved antibodies to improve and enhance the inherent power of the immune system to target and destroy tumor cells, while potentially offering a tolerable safety profile. Indapta’s universal, allogeneic G-NK cell therapy is intended to be used in combination with the numerous FDA-approved antibodies to treat a variety of cancers.
Our Science
Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of antibody therapy in multiple cancers. Indapta has enhanced the anti-tumor activity of its G-NK cell therapy via specific G-NK cell subset selection and its proprietary manufacturing process. This produces an NK cell therapy that demonstrates higher efficacy, persistence and enhanced cryopreservation than standard monoclonal antibody therapy or standard monoclonal antibody therapy combined with conventional NK cells.
Engagement of Indapta’s G-NK cell therapy with an antibody bound to a tumor target initiates the release of dramatically more cancer killing compounds than that produced by conventional NK cells. This allows for increased efficacy and potentially less frequent dosing. Indapta’s off-the-shelf G-NK cell therapy is further differentiated in that it is a cell banked product with low variability.